Here are five takeaways:
1. The data was presented in oral and poster sessions at The International Liver Congress 2016 in Barcelona, Spain.
2. The first agent, simtuzumab, is a monoclonal antibody that is selective for LOXL2, an extracellular matrix enzyme that promotes fibrosis via the cross-linkage of collagen fibers.
3. The second agent, GS-4997, is a small-molecule inhibitor of apoptosis signal-regulating kinase 1, which promotes inflammation, apoptosis and fibrosis in settings of increased oxidative stress associated with NASH pathogenesis.
4. The third agent, GS-9674, is a selective non-steroidal agonist of the Farnesoid X receptor, a nuclear hormone receptor that is highly expressed in the gastrointestinal tract and liver.
5. Gilead Sciences is a Foster City, Calif.-based biopharmaceutical company that discovers, develops and commercializes therapeutics.
More articles on GI & endoscopy:
25 patients to sue Baystate Noble Hospital for potential exposure to HCV, HBV & HIV: 4 things to know
Patients with flat adenomas may be at higher risk of multiple lesions: 3 insights
FDA approves 1st CRC screening blood test: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.